Gsk (GSK) Receivables - Net (2016 - 2025)

Gsk (GSK) has 10 years of Receivables - Net data on file, last reported at $9.9 billion in Q4 2025.

• In Q4 2025, Receivables - Net rose 13.26% year-over-year to $9.9 billion; the TTM figure through Dec 2025 stood at $9.9 billion (up 13.26% YoY), while the FY2025 annual figure was $9.9 billion, up 13.26% from the prior year.
• Receivables - Net climbed to $9.9 billion in Q4 2025, from $8.8 billion in the prior quarter.
• Across five years, Receivables - Net topped out at $10.6 billion in Q4 2021 and bottomed at $8.3 billion in Q4 2022.
• A 5-year average of $9.3 billion and a median of $9.2 billion in 2023 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2021 — Receivables - Net rose 15.42% — and 2022, when it dropped 21.92%.
• Year by year, Receivables - Net stood at $10.6 billion in 2021, then dropped by 21.92% to $8.3 billion in 2022, then increased by 10.8% to $9.2 billion in 2023, then slipped by 4.28% to $8.8 billion in 2024, then climbed by 13.26% to $9.9 billion in 2025.
• The last three Receivables - Net figures came in at $9.9 billion (Q4 2025), $8.8 billion (Q4 2024), and $9.2 billion (Q4 2023), per Business Quant data.

Peer Comparison